[1]黄斌,周石.TACE联舍氩氦刀冷冻术治疗巨块型肝细胞癌的 临床研究[J].介入放射学杂志,2011,(01):28-31.
　HUANG Bin,ZHOU Shi..Transcatheter arterial chemoembolization combined with Argon-Helium cryoablation for the treatment of hepatocellular carcinoma of giant lump type: a clinical study[J].journal interventional radiology,2011,(01):28-31.
点击复制

TACE联舍氩氦刀冷冻术治疗巨块型肝细胞癌的 临床研究()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2011年01期
页码:
28-31
栏目:
肿瘤介入
出版日期:
2011-01-15

文章信息/Info

Title:
Transcatheter arterial chemoembolization combined with Argon-Helium cryoablation for the treatment of hepatocellular carcinoma of giant lump type: a clinical study
作者:
黄斌; 周石
410016  长沙  湖南省肿瘤医院放射诊疗科；贵阳医学院附属医院介入科
Author(s):
HUANG Bin;  ZHOU Shi.
Department of Radiology, Hunan Provincial Tumor Hospital, Changsha 410009, China
关键词:
肝动脉灌注化疗栓塞; 　氩氦刀冷冻消融术; 　巨块型肝细胞癌
分类号:
Ｒ７３５.７
文献标志码:
Ａ
摘要:
目的　　　探讨ＴＡＣＥ采用联合氩氦刀冷冻术治疗巨块型肝细胞癌的疗效。方法　　　收集湖南省肿瘤医院２００１年１月－ ２００７年５月采用ＴＡＣＥ联合氩氦刀冷冻消融治疗病灶大于５　ｃｍ肝细胞癌５６例（治疗组），并筛选同期在性别、年龄、病理等无显著差异的单纯ＴＡＣＥ治疗的例数相同的病例（对照组）。分析比较两组１、２、３年生存率，治疗前后临床症状的改善，肝功能、血清肿瘤标志物（ＡＦＰ）和肿瘤影像学改变（ＣＴ 或ＭＲＩ）。结果　　　治疗组１、２、３年生存率分别为７４．５％、６８．４％和４０．７％。平均生存期２１个月，３个月临床症状缓解率为８０．４％。６个月内ＣＴ、ＭＲＩ提示治疗组病灶完全坏死者占１５．５％，病灶明显缩小者占５３．５％。对照组１、２、３年生存率为５２．５％、４４．１％和２８．１％，平均生存期１３个月，３个月临床症状的缓解率为５７．１％。６个月内对照组ＣＴ、ＭＲＩ 提示病灶完全坏死者占７．９％，病灶明显缩小者占２８．８％。两组间差异均有统计学意义（Ｐ值均 ＜ ０．０５）。结论　　　ＴＡＣＥ联合氩氦刀冷冻消融是治疗巨块型肝细胞癌是一种有效的联合治疗方法，近期疗效明显，为巨块型肝细胞癌提供了新的治疗途径。

参考文献/References:

[1] 保志军, 竺 越, 于晓峰, 等. 中晚期原发性肝癌介入治疗的疗效和经济学评价[J]. 肝脏, 2000, 5: 221.
[2] 郭伟剑, 于尔辛. 原发性肝癌的综合治疗研究进展[J]. 中国癌症杂志, 2000, 10: 275 - 277.
[3] Hinshaw JL, Lee FT Jr. Cryoablation for liver cancer[J]. Tech Vasc Interv Radiol, 2007, 10: 47 - 57.
[4] 李征然, 朱廉顺, 单 鸿, 等. CT导向下射频消融联合TACE治疗原发性肝癌[J]. 南方医科大学学报, 2007, 27: 1749 - 1751.
[5] Clavien PA, Kang KJ, Selzner N, et al. Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis[J]. J Gastrointest Surg, 2002, 6: 95 - 101.
[6] Mok KT, Wang BW, Lo GH, et al. Multimodality management of hepatocellular carcinoma larger than 10 cm[J]. J Am Coll Surg, 2003, 197: 730 - 738.
[7] Livraghi T, Meloni F, Morabito A, et al. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center[J]. Liver Transpl, 2004, 10: S98 - S106.
[8] Li N, Zhou J, Weng D, et al. Adjuvant adenovirus mediated delivery of herpes simplex vius thymidins kinase administration improves outcome of liver transplantation in Patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2007, 13: 5847 - 5854.
[9] Kulik LM, Atassi B, Van Holsbeeck L, et al. Yttrium-90 microspheres(TheraSphere) treatment of unresectable hepatoce-llular carcinoma: downstaging to resection,RFA and bridge to transplantation[J]. J Surg Oncol, 2006, 94: 572 - 586.

相似文献/References:

[1]朱芳来,凌安生.经动脉灌注化疗栓塞联合经皮无水乙醇注射治疗原发性肝癌临床研究[J].介入放射学杂志,2008,(04):286.
　ZHU Fanglai,LING Ansheng.Clinical study of TACE combined PEI in treatment of primary hepatic carcinoma[J].journal interventional radiology,2008,(01):286.

备注/Memo

备注/Memo:
收稿日期：２０１００７０７
更新日期/Last Update: 2011-01-15